Maurizio Scaltriti

List of Publications by Year
in descending order

123	16,633	23567	20961
papers	citations	58 h-index	115 g-index

129	129	129	23384
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	NTRK fusion-positive cancers and TRK inhibitor therapy. Nature Reviews Clinical Oncology, 2018, 15, 731-747.	27.6	975
2	AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity. Cancer Cell, 2011, 19, 58-71.	16.8	867
3	The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy. Clinical Cancer Research, 2006, 12, 5268-5272.	7.0	776
4	Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 628-638.	6.3	769
5	NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. Cancer Research, 2008, 68, 8022-8030.	0.9	726
6	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
7	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	27.8	572
8	PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. Cancer Discovery, 2012, 2, 1036-1047.	9.4	507
9	Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor. Nature, 2015, 518, 240-244.	27.8	486
10	Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235. Cancer Research, 2008, 68, 9221-9230.	0.9	474
11	Targeted drug delivery strategies for precision medicines. Nature Reviews Materials, 2021, 6, 351-370.	48.7	388
12	mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling. Cancer Discovery, 2011, 1, 248-259.	9.4	385
13	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology, 2018, 36, 2532-2537.	1.6	381
14	A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusionâ€“Positive Solid Tumors. Cancer Discovery, 2017, 7, 963-972.	9.4	331
15	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 2018, 34, 893-905.e8.	16.8	307
16	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3761-3766.	7.1	291
17	Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes. Clinical Cancer Research, 2009, 15, 7381-7388.	7.0	281
18	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptorâ€“positive breast cancer. Science Translational Medicine, 2015, 7, 283ra51.	12.4	276

#	Article	IF	Citations
19	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	9.4	275
20	AXL Mediates Resistance to PI3KÎ± Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell, 2015, 27, 533-546.	16.8	263
21	ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Annals of Oncology, 2019, 30, 1417-1427.	1.2	263
22	mTORC1 Inhibition Is Required for Sensitivity to PI3K p110Î± Inhibitors in PIK3CA -Mutant Breast Cancer. Science Translational Medicine, 2013, 5, 196ra99.	12.4	251
23	PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science, 2017, 355, 1324-1330.	12.6	217
24	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Reports, 2016, 17, 2367-2381.	6.4	215
25	Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO Journal, 2006, 25, 3234-3244.	7.8	196
26	PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nature Medicine, 2016, 22, 1303-1313.	30.7	188
27	PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3KÎ± Inhibition. Cancer Cell, 2016, 30, 229-242.	16.8	187
28	Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3KÎ± inhibitors. Science, 2019, 366, 714-723.	12.6	185
29	Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy. Clinical Cancer Research, 2012, 18, 2603-2612.	7.0	154
30	P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Science Translational Medicine, 2016, 8, 345ra87.	12.4	152
31	A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis. Molecular and Cellular Biology, 2009, 29, 3319-3331.	2.3	150
32	HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	9.4	149
33	Somatic PIK3CA mutations as a driver of sporadic venous malformations. Science Translational Medicine, 2016, 8, 332ra42.	12.4	147
34	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine, 2019, 25, 1422-1427.	30.7	144
35	ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nature Genetics, 2020, 52, 198-207.	21.4	140
36	Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2â€“Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research, 2010, 16, 2688-2695.	7.0	137

#	Article	IF	Citations
37	Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. Science Signaling, 2014, 7, ra29.	3.6	123
38	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	9.4	115
39	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer Research, 2019, 79, 1047-1053.	0.9	112
40	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. Journal of Clinical Investigation, 2013, 123, 2551-2563.	8.2	108
41	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. Cancer Discovery, 2016, 6, 1134-1147.	9.4	106
42	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. Clinical Cancer Research, 2020, 26, 1624-1632.	7.0	103
43	Intracellular Clusterin Induces G2-M Phase Arrest and Cell Death in PC-3 Prostate Cancer Cells1. Cancer Research, 2004, 64, 6174-6182.	0.9	97
44	Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. International Journal of Cancer, 2004, 108, 23-30.	5.1	96
45	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	13.2	96
46	Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clinical Cancer Research, 2016, 22, 1313-1317.	7.0	92
47	Overview of the relevance of PI3K pathway in HR-positive breast cancer. Annals of Oncology, 2019, 30, x3-x11.	1.2	92
48	Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma. Nature Communications, 2017, 8, 14292.	12.8	90
49	Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 198-213.	9.4	83
50	Clusterin (SGP-2) transient overexpression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene, 2002, 21, 4328-4334.	5.9	79
51	Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell Death and Disease, 2019, 10, 534.	6.3	78
52	High HER2 protein levels correlate with increased survival in breast cancer patients treated with antiâ€HER2 therapy. Molecular Oncology, 2016, 10, 138-147.	4.6	76
53	Clusterin-Mediated Apoptosis Is Regulated by Adenomatous Polyposis Coli and Is p21 Dependent but p53 Independent. Cancer Research, 2004, 64, 7412-7419.	0.9	74
54	Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068. Clinical Cancer Research, 2013, 19, 6976-6986.	7.0	72

#	Article	IF	Citations
55	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. Clinical Cancer Research, 2015, 21, 569-576.	7.0	71
56	Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing ActivatingPIK3CAAlterations. Clinical Cancer Research, 2016, 22, 2009-2019.	7.0	70
57	The prognostic value of PI3K mutational status in breast cancer: A metaâ€analysis. Journal of Cellular Biochemistry, 2018, 119, 4287-4292.	2.6	69
58	FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell, 2020, 38, 534-550.e9.	16.8	67
59	Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. OncoImmunology, 2017, 6, e1267891.	4.6	66
60	The present and future of PI3K inhibitors for cancer therapy. Nature Cancer, 2021, 2, 587-597.	13.2	63
61	p95HER2â€“T cell bispecific antibody for breast cancer treatment. Science Translational Medicine, 2018, 10, .	12.4	59
62	Molecular Pathways: Targeting Hsp90â€”Who Benefits and Who Does Not. Clinical Cancer Research, 2012, 18, 4508-4513.	7.0	56
63	Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. ESMO Open, 2017, 2, e000253.	4.5	56
64	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients withAKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2020, 26, 3947-3957.	7.0	54
65	Clusterin Isoforms Differentially Affect Growth and Motility of Prostate Cells: Possible Implications in Prostate Tumorigenesis. Cancer Research, 2007, 67, 10325-10333.	0.9	53
66	Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. Nature Communications, 2017, 8, 15987.	12.8	53
67	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 2018, 11, .	3.6	53
68	Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3030-3035.	7.1	52
69	Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. Molecular Cancer Therapeutics, 2011, 10, 817-824.	4.1	50
70	A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer. Cancer Convergence, 2017, 1, 5.	8.0	50
71	Biomarkers of drugs targeting <scp>HER</scp>â€family signalling in cancer. Journal of Pathology, 2014, 232, 219-229.	4.5	49
72	AKT signaling in ERBB2-amplified breast cancer. , 2016, 158, 63-70.		49

#	Article	IF	Citations
73	PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression. Cell Reports, 2019, 27, 294-306.e5.	6.4	49
74	A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers. Cancer Research, 2010, 70, 8537-8546.	0.9	47
75	Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. International Journal of Infectious Diseases, 2021, 104, 433-440.	3.3	47
76	The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nature Communications, 2022, 13, 1450.	12.8	47
77	Stratification and therapeutic potential of PML in metastatic breast cancer. Nature Communications, 2016, 7, 12595.	12.8	45
78	Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. Journal of Clinical Investigation, 2018, 128, 3819-3825.	8.2	45
79	Prevalence and role of HER2 mutations in cancer. , 2019, 199, 188-196.		44
80	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation. Cancer Discovery, 2013, 3, 1238-1244.	9.4	43
81	Quantification of HER family receptors in breast cancer. Breast Cancer Research, 2015, 17, 53.	5.0	39
82	Metabolic Imaging Detects Resistance to PI3KÎ± Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. Cancer Cell, 2020, 38, 516-533.e9.	16.8	38
83	Potential biomarkers of longâ€term benefit from singleâ€agent trastuzumab or lapatinib in HER2â€positive metastatic breast cancer. Molecular Oncology, 2014, 8, 20-26.	4.6	37
84	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature Communications, 2020, 11, 1975.	12.8	37
85	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. Journal of the National Cancer Institute, 2014, 106, .	6.3	36
86	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. Cancer Discovery, 2021, 11, 126-141.	9.4	34
87	Molecular classification of green tea catechin-sensitive and green tea catechin-resistant prostate cancer in the TRAMP mice model by quantitative real-time PCR gene profiling. Carcinogenesis, 2006, 27, 1047-1053.	2.8	31
88	Phase and context shape the function of composite oncogenic mutations. Nature, 2020, 582, 100-103.	27.8	31
89	Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2015, 24, 421-431.	4.1	29
90	Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. Journal of Nuclear Medicine, 2016, 57, 1413-1419.	5.0	28

#	Article	IF	Citations
91	Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2594-E2603.	7.1	23
92	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients withPIK3CA-Mutant Cancers. Clinical Cancer Research, 2021, 27, 447-459.	7.0	22
93	Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway. Molecular Oncology, 2019, 13, 1684-1692.	4.6	21
94	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clinical Cancer Research, 2020, 26, 3720-3731.	7.0	21
95	Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study. Cancer Research, 2003, 63, 3469-72.	0.9	21
96	MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer. International Journal of Cancer, 2019, 145, 748-762.	5.1	20
97	Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3KÎ± Inhibitors. Cancer Research, 2021, 81, 2470-2480.	0.9	20
98	MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. , 2022, 10, e003917.		19
99	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted byTP53Mutation in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5499-5510.	7.0	18
100	Molecular mechanisms of assembly and TRIP13-mediated remodeling of the human Shieldin complex. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2024512118.	7.1	16
101	ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. Cells, 2021, 10, 1659.	4.1	16
102	PI3K pathway inhibitors: better not left alone. Current Pharmaceutical Design, 2013, 19, 895-906.	1.9	16
103	UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2103592118.	7.1	14
104	Cell Lineâ€“Specific Network Models of ER+ Breast Cancer Identify Potential PI3KÎ± Inhibitor Resistance Mechanisms and Drug Combinations. Cancer Research, 2021, 81, 4603-4617.	0.9	13
105	HighFGFR1â€“4mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clinical Cancer Research, 2022, 28, 137-149.	7.0	12
106	Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors. Cell Death and Disease, 2021, 12, 179.	6.3	11
107	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Medicine, 2020, 12, 78.	8.2	10
108	Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Molecular and Cellular Oncology, 2014, 1, e963447.	0.7	9

#	Article	IF	Citations
109	The emerging role of serum/glucocorticoid-regulated kinases in cancer. Cell Cycle, 2017, 16, 5-6.	2.6	8
110	Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies. Npj Breast Cancer, 2021, 7, 124.	5.2	7
111	CDK 4/6 Inhibition Overcomes Acquired and Inherent Resistance to PI3KÎ± Inhibition in Pre-Clinical Models of Head and Neck Squamous Cell Carcinoma. Journal of Clinical Medicine, 2020, 9, 3214.	2.4	6
112	The Oncogenic PI3K-Induced Transcriptomic Landscape Reveals Key Functions in Splicing and Gene Expression Regulation. Cancer Research, 2022, 82, 2269-2280.	0.9	6
113	Therapeutic Antibodies in Breast Cancer. Seminars in Oncology, 2014, 41, 576-588.	2.2	3
114	Mechanisms of Resistance to PI3K and AKT Inhibitors. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 117-146.	0.1	3
115	First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Frontiers in Oncology, 2021, 11, 744112.	2.8	3
116	Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas. Modern Pathology, 2021, , .	5.5	3
117	In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System. Journal of Visualized Experiments, 2020, , .	0.3	2
118	How a new drug is born. European Heart Journal, 2021, 42, 3039-3041.	2.2	0
119	JosÃ© Manuel Baselga (1959â€“2021). Science, 2021, 372, 350-350.	12.6	0
120	JosÃ© Baselga (1959â€“2021). Cancer Cell, 2021, 39, 581-582.	16.8	0
121	JosÃ© Baselga 1959â€“2021. Nature Cancer, 2021, 2, 479-480.	13.2	0
122	Characterization of Ntrk fusions and Therapeutic Response to Ntrk Inhibition in Hematologic Malignancies. Blood, 2017, 130, 794-794.	1.4	0
123	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. SSRN Electronic Journal, 0, , .	0.4	0